# US 2026/0295007 A1 · Beta-caseins in infant milk formula and use for reducing regurgitation episodes in infants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0295007 A1
- Document ID: US20260295007A1
- Status: Published application
- Kind: A1
- Application number: 19/478,677
- Filed: 2024-04-24
- Published: 2026-10-01
- Earliest claimed: 2023-04-25
- Assignees: The A2 Milk Company Limited
- Applicants: The A2 Milk Company Limited
- Inventors: Andrew John Clarke; Julia Zhu
- Web page: https://patentgrep.com/patent/US20260295007A1

## CPC

- A61K 38/1709: {from mammals}
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 35/20: Milk; Whey; Colostrum
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Reducing the frequency of regurgitation episodes in an infant by providing infant milk formula manufactured from milk which comprises beta-casein, wherein the beta-casein comprises less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

## Claims

### Claim 1

A method for reducing the frequency of regurgitation episodes in an infant by providing infant milk formula to the infant for ingestion, wherein the milk used in the manufacture of the infant milk formula contains beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

### Claim 2 (depends on 1)

A method as claimed in claim 1, wherein the beta-casein comprises less than 30% by weight of any one or more of beta-casein variants A1, B, C, F, G, H1 and H2.

### Claim 3 (depends on 1, 2)

A method as claimed in claim 1 or claim 2, wherein the beta-casein comprises less than 25% by weight of beta-casein A1.

### Claim 4 (depends on 1, 2, 3)

A method as claimed in any one of claims 1 to 3, wherein the beta-casein comprises less than 10% by weight beta-casein A1.

### Claim 5 (depends on 1, 2, 3, 4)

A method as claimed in any one of claims 1 to 4, wherein the beta-casein comprises less than 5% by weight beta-casein A1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A method as claimed in any one of claims 1 to 5, wherein the beta-casein comprises less than 1% by weight beta-casein A1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method as claimed in any one of claims 1 to 6, wherein the beta-casein comprises no beta-casein A1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method as claimed in any one of claims 1 to 7, wherein the beta-casein comprises at least 70% by weight of beta-caseins having proline at position 67 of the beta-casein amino acid sequence.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method as claimed in any one of claims 1 to 8, wherein the beta-casein comprises at least 70% by weight of any one or more of beta-casein variants A2, A3, D, E and I.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method as claimed in any one of claims 1 to 9, wherein the beta-casein comprises at least 75% by weight beta-casein A2.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method as claimed in any one of claims 1 to 10, wherein the beta-casein comprises at least 90% by weight beta-casein A2.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method as claimed in any one of claims 1 to 11, wherein the beta-casein comprises at least 95% by weight beta-casein A2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method as claimed in any one of claims 1 to 12, wherein the beta-casein comprises at least 99% by weight beta-casein A2.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method as claimed in any one of claims 1 to 13, wherein the beta-casein comprises 100% beta-casein A2.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method as claimed in any one of claims 1 to 14, wherein the infant has an age less than six months or less than three months.

### Claim 16

A method for reducing the frequency of regurgitation episodes in an infant by feeding infant milk formula to the infant, wherein the milk used in the manufacture of the infant milk formula contains beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

### Claim 17

A method for reducing the frequency of regurgitation episodes in an infant having a diet comprising infant milk formula where the infant milk formula contains beta-casein comprising at least 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence, by replacing the infant milk formula with a replacement infant milk formula manufactured from milk containing beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

### Claim 18

A method for reducing the frequency of regurgitation episodes in an infant having a diet comprising a first infant milk formula, wherein the first infant milk formula is replaced with a second infant milk formula in the diet of the infant;
wherein the first infant milk formula contains beta-casein comprising at least 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence; and
wherein the second infant milk formula is manufactured from milk containing beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

### Claim 19

Infant milk formula for reducing the frequency of regurgitation episodes in an infant which infant milk formula is manufactured from milk containing beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.

### Claim 20

The use of bovine milk in the manufacture of infant milk formula for reducing the frequency of regurgitation episodes in an infant, wherein the milk contains beta-casein comprising less than 30% by weight of beta-caseins having histidine at position 67 of the beta-casein amino acid sequence.
